Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Intangibles (2019 - 2023)

ADC Therapeutics has reported Intangibles over the past 5 years, most recently at $12.4 million for Q3 2023.

  • Quarterly results put Intangibles at $12.4 million for Q3 2023, down 15.34% from a year ago — trailing twelve months through Sep 2023 was $12.4 million (down 15.34% YoY), and the annual figure for FY2022 was $14.4 million, up 105628.17%.
  • Intangibles reached $12.4 million in Q3 2023 per ADCT's latest filing, down from $13.5 million in the prior quarter.
  • Across five years, Intangibles topped out at $14.6 million in Q3 2022 and bottomed at $8825.0 in Q2 2020.
  • Median Intangibles over the past 5 years was $12.0 million (2021), compared with a mean of $10.3 million.
  • The largest annual shift saw Intangibles surged 135990.65% in 2021 before it dropped 15.34% in 2023.
  • Over 5 years, Intangibles stood at $5.9 million in 2019, then increased by 28.5% to $7.6 million in 2020, then soared by 45.78% to $11.1 million in 2021, then rose by 3.19% to $11.4 million in 2022, then increased by 8.05% to $12.4 million in 2023.
  • Business Quant data shows Intangibles for ADCT at $12.4 million in Q3 2023, $13.5 million in Q2 2023, and $13.6 million in Q1 2023.